The Drugs Built for CKM: How GLP-1s, SGLT2 Inhibitors, and Finerenone Are Rewriting Cardio-Renal-Metabolic Care

If Cardiovascular-Kidney-Metabolic (CKM) syndrome represents a new unified clinical risk framework spanning the heart, kidneys, and metabolism, the most interesting development is that the pharmaceutical industry got there first — almost by accident. Three drug classes developed originally for diabetes are turning out to be exactly the kind of multi-system therapy the CKM framework calls for, and the 2026 AHA/ACC/ADA/ASN guideline formally recommends them as first-line CKM management tools.

GLP-1 receptor agonists: the FLOW trial changed the conversation

GLP-1 drugs (semaglutide — Ozempic/Wegovy — and related compounds) were developed and approved for diabetes and, later, obesity. The FLOW trial, whose full results were presented and later analyzed in subgroup data through 2025, provided the first clear randomized-trial evidence that a GLP-1 receptor agonist directly slows the progression of kidney disease and reduces cardiovascular mortality in people with type 2 diabetes and CKD — not just as a side effect of better blood sugar control or weight loss, but as an independent kidney and cardiovascular protective effect. That's a big deal mechanistically: it means a drug developed for one node of the CKM triangle (metabolism) has now demonstrated hard outcomes evidence for two of the other three (kidney, cardiovascular).

SGLT2 inhibitors: already there, with the longer track record

SGLT2 inhibitors (dapagliflozin/Forxiga, empagliflozin/Jardiance, canagliflozin/Invokana) have a longer clinical evidence base for cross-system protection, with multiple large outcomes trials showing reduced risk of kidney disease progression and heart failure hospitalization, independent of their glucose-lowering effect. They're now a Class I recommendation in the new CKM guideline for patients with CKD and/or heart failure, regardless of diabetes status — a meaningful expansion beyond their original diabetes-only approval population.

Finerenone: the newer addition to the toolkit

Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, adds a third mechanism to the CKM toolkit — targeting the inflammatory and fibrotic pathways in the kidney and cardiovascular system that GLP-1s and SGLT2 inhibitors don't directly address. Network meta-analyses comparing finerenone, SGLT2 inhibitors, and GLP-1 receptor agonists in patients with type 2 diabetes and CKD have found the three classes broadly comparable on major cardiovascular events, all-cause mortality, and cardiovascular death — with SGLT2 inhibitors showing a specific edge on slowing kidney-specific events. The clinical and research direction now points toward combination therapy — layering these mechanisms rather than picking one — as the likely future standard of care for high-stage CKM patients.

The commercial angle: three drug classes, one converging market

This convergence is a genuine commercial event, not just a scientific one. Drugs developed and marketed for separate, siloed indications — diabetes (GLP-1s, SGLT2i), heart failure (SGLT2i), and CKD (finerenone) — are now competing and complementing each other across a single, unified CKM treatment paradigm that, per the prevalence data, potentially applies to the majority of US adults. For the companies behind these franchises — Novo Nordisk and Eli Lilly on GLP-1s, AstraZeneca and Boehringer Ingelheim/Lilly on SGLT2 inhibitors, Bayer on finerenone — the CKM framework's formal codification into a multi-society guideline is effectively a market-expansion event: it gives prescribers formal guideline backing to reach for these drugs earlier and in more patients than the original diabetes-only label ever justified.

The skeptical read

The clinical evidence behind each individual drug class is genuinely strong — these are large, well-run randomized outcomes trials, not surrogate-endpoint studies. What's less proven is the combination-therapy thesis: stacking two or three of these mechanisms in the same patient is now common clinical practice and guideline-endorsed, but head-to-head or triple-combination outcomes trials comparing combination regimens against single-agent therapy are still limited. The guideline is making a reasonable evidence-based bet on mechanistic complementarity; whether triple therapy meaningfully outperforms well-selected monotherapy in hard outcomes, at acceptable cost and side-effect burden, is the trial data still to come.

---

Todd Colpron is the Managing Partner of Eliakim Capital, a boutique principal investment and strategic advisory firm focused on life sciences, capital strategy, and long-term value creation. He works with select management teams navigating growth, investor communications, and capital formation, while evaluating opportunities where Eliakim Capital’s experience, relationships, and investment perspective can add meaningful value. The firm may also invest its own capital when an opportunity demonstrates strong strategic alignment and investment merit.